Breast cancer is the most commonly diagnosed cancer in the United Kingdom. Around 56,000 people are diagnosed each year — roughly 55,500 women and 400 men — and around 11,500 women die from the disease annually. This guide explains UK incidence, survival, NHS screening, treatment access and health inequalities — and why the gap between Britain and low-income countries is far larger than any high-income comparison.
UK breast cancer survival today
Five-year breast cancer survival in the UK is approximately 85–87%, and ten-year survival around 76–80%. Survival is driven overwhelmingly by stage at diagnosis: roughly 99% at Stage I, falling to around 28% at Stage IV. UK survival has more than doubled over the past 50 years — from around 40% five-year survival in the 1970s to over 85% today.
NHS data for 2024–25 shows that 19,291 cancers were detected through routine screening — a detection rate of 9.0 cases per 1,000 women screened, up from 8.5 per 1,000 the previous year. In 2024–25, 70.6% of invited women took up their mammogram — 2.15 million women screened in a single year.
NHS breast screening: who is invited and when
- England: women aged 50–71 invited every three years; trial exploring expansion to 47–73; women over 71 can self-refer.
- Scotland, Wales and Northern Ireland: similar three-year programmes from age 50 (upper invitation age varies slightly by nation).
- All NHS screening is free at point of care.
- Women outside invited ages with symptoms should see their GP promptly — do not wait for a screening letter.
Health inequalities within the UK
South Asian women (Indian, Pakistani, Bangladeshi and Sri Lankan heritage) have lower breast cancer incidence than white British women but are more likely to be diagnosed at a later stage. Barriers include language, cultural concerns about modesty, lower awareness of screening, and in some communities, lower trust in healthcare services. Closing this gap requires targeted, culturally sensitive outreach alongside universal NHS access.
NHS treatment: free at point of use
In the UK, breast cancer treatment through the NHS is free at point of use for all patients — surgery, chemotherapy, radiotherapy, hormone therapy and follow-up are covered regardless of income. A clinical nurse specialist (CNS) or breast care nurse usually coordinates care through a multidisciplinary team.
Dense breast tissue and NHS screening
Dense breast tissue makes mammograms harder to read — dense tissue and potential tumours both appear white on X-ray. Around 40% of women have dense breasts. The NHS does not routinely notify patients of their density category after screening, though radiologists account for density when reading mammograms. You can ask your GP or breast screening unit about your density, especially with additional risk factors.
Emerging treatments reaching NHS patients
- HER2-low disease: trastuzumab deruxtecan (Enhertu) targets HER2-low tumours — around 55–60% of all breast cancers.
- Immunotherapy: pembrolizumab (Keytruda) for early-stage, high-risk triple-negative breast cancer.
- AI-assisted mammography: trialled within NHS screening centres alongside human radiologists.
- CDK4/6 inhibitors: standard in metastatic hormone receptor-positive disease.
The global survival gap that matters most
UK survival improvements are real and significant — but modest compared to the gap between Britain and the developing world. In Pakistan, Bangladesh and Indonesia, five-year breast cancer survival can be below 40%. Without organised screening, most cancers are found at Stage III or Stage IV.
A woman diagnosed with Stage I breast cancer in the UK has a 98–99% five-year survival rate. A woman in rural Pakistan with the same cancer, found at Stage III because she had no access to screening, faces survival odds below 50%. The biological cancer is identical. The difference is entirely about whether she was found in time. This is the gap that Breast Cancer Charity — an initiative of World Aid Network — exists to close.
Share this article